Intensive Care Medicine

, Volume 39, Issue 7, pp 1181–1189

Prognostic value of troponins in sepsis: a meta-analysis

  • Francis Bessière
  • Safia Khenifer
  • Julie Dubourg
  • Isabelle Durieu
  • Jean-Christophe Lega
Systematic Review

DOI: 10.1007/s00134-013-2902-3

Cite this article as:
Bessière, F., Khenifer, S., Dubourg, J. et al. Intensive Care Med (2013) 39: 1181. doi:10.1007/s00134-013-2902-3

Abstract

Rationale

The role of biomarkers such as troponin in risk stratification of sepsis is still debated. The aim of this meta-analysis is to assess the relation between troponin elevation in sepsis and mortality.

Methods

All observational studies from Embase, Medline and those manually searched up to September 2010 were included. Studies identified were those which reported on patients with a diagnosis of sepsis and if a 2 × 2 table could be constructed based on troponins and death. We pooled the relative risk (RR) and odds-ratio (OR) using the inverse variance method in studies that conducted univariate and multivariable (adjusted) analysis.

Main results

Thirteen studies encompassing 1,227 patients were included. The prevalence of elevated troponin was 61 % ([95 %] CI 58–64 %). Elevated troponin was significantly associated with all-cause mortality (RR 1.91; CI 1.63–2.24), with homogeneity across studies. In adjusted analysis (four studies comprising 791 patients) according to prognostic scores, elevated troponin was associated with an increased risk of death (OR 1.92; CI 1.35–2.74). The area under the ROC curve was 0.68 (CI 0.63–0.71). Pooled sensitivity and specificity were 77 % (CI 61–88) and 47 % (CI 30–64) with heterogeneity across studies. It corresponded to positive and negative likelihood ratios of 1.50 (95 % CI: 1.20–1.90) and 0.49 (CI 0.38–0.64), respectively.

Conclusions

Elevated troponin identifies a subset of patients with sepsis at higher risk of death. Further studies are needed to define the precise role of troponins and their optimal cut-offs.

Keywords

Sepsis Prognosis Sensitivity Specificity Meta-analysis 

Supplementary material

134_2013_2902_MOESM1_ESM.doc (111 kb)
Supplementary material 1 (DOC 111 kb)
134_2013_2902_MOESM2_ESM.doc (58 kb)
Supplementary material 2 (DOC 59 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2013

Authors and Affiliations

  • Francis Bessière
    • 1
  • Safia Khenifer
    • 1
  • Julie Dubourg
    • 2
  • Isabelle Durieu
    • 1
  • Jean-Christophe Lega
    • 1
    • 3
  1. 1.Department of Vascular and Internal MedicineHôpital Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1VilleurbanneFrance
  2. 2.Department of Clinical PharmacologyUniversité Claude Bernard Lyon 1LyonFrance
  3. 3.Department of Internal and Vascular MedicineHospices Civils de Lyon de Lyon, Centre Hospitalier Lyon SudPierre-BéniteFrance